venerdì, 26 novembre 2021
18 Novembre 2019

Lenalidomide/Rituximab Combo Nears EU Approval for Follicular Lymphoma

November 15, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the combination of lenalidomide and rituximab for the treatment of adult patients with grade 1 to 3a previously treated follicular lymphoma. The positive opinion is primarily based on results from the phase III AUGMENT study, which showed that the combination reduced the risk of disease progression or death by 54% versus … (leggi tutto)